We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





First FDA-Authorized COVID-19 Test Identifies Specific SARS-CoV-2 Lineages

By LabMedica International staff writers
Posted on 20 Jun 2022

Next-generation sequencing (NGS) provides an effective, unbiased way to identify new coronavirus strains and other pathogens without prior knowledge of organisms. More...

Growing concern over fast spreading, novel variants of the SARS-CoV-2 coronavirus, such as the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P1, Brazil), Delta (B.1.617.2) and Omicron (B.1.1.529) strains, highlights the need for more sequencing to detect mutations quickly and prevent the spread of new strains. Now, the U.S. Food and Drug Administration (FDA) has authorized the first test for the identification and differentiation of SARS-CoV-2 Phylogenetic Assignment of Named Global Outbreak (PANGO) lineages, which are genetic variations in circulating virus strains.

LabCorp Diagnostics (Burlington, NC, USA) has received an emergency use authorization (EUA) from the FDA for its VirSeq SARS-CoV-2 NGS Test on the PacBio Sequel II sequencing system. The system provides access to high throughput, cost effective, highly accurate long-read sequencing. VirSeq SARS-CoV-2 NGS Test can identify specific SARS-CoV-2 strains in patient samples.

The VirSeq SARS-CoV-2 NGS Test is a PacBio Sequel II-based whole genome sequencing assay used for the determination of PANGO lineage from extracted RNA of SARS-CoV-2 positive samples identified using Labcorp’s COVID-19 RT-PCR Test or Labcorp SARS-CoV-2 & Influenza A/B Assay. The SARS-CoV-2 probe set used in the assay contains ~1000 tiled Molecular Loop Inversion Probes (MIPS) designed to amplify RNA that has been reverse transcribed to cDNA from 99.6% of the SARS-CoV-2 genome with most bases covered by 22 MIPs. The product synthesized in-between the MIPS is enriched and has sample specific molecular barcodes added via amplification followed by sequencing.

The test could be used by health care providers if they believe, based on a patient medical history and other diagnostic information, that strain-specific information could help determine appropriate patient treatment. The test is not intended to be used in a primary diagnosis of SARS-CoV-2 infection, to confirm the presence of infection, or for identification of specific SARS-CoV-2 genomic mutations.

Related Links:
LabCorp Diagnostics


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.